LifeGlue raises EUR 705,000 seed round
Tampere University spin-out LifeGlue Technologies raises EUR 705,000 in seed funding from business angels in Finland, Estonia, and Lithuania, together with Innovestor. The money will go toward pharmaceutical-grade production of its material for growing human tissue in the lab.
The Tampere-based company makes Glue4Life, a gel that gives cells a structure to grow and organize into tissue such as brain, liver, and nerve. Unlike the animal-derived gels common today, it is made from hyaluronic acid, has a precisely defined composition, and is easier to get approved for use in humans.
LifeGlue does not develop therapies itself. Instead, it supplies the material to companies and research groups that do. It began commercial operations in December 2024 and already has 15 paying customers in Europe, the US, and Australia.
“There are hundreds of companies and research groups in tissue engineering competing to be the first to get their graft to patients. We don’t have to guess the winner, because LifeGlue succeeds whenever any of them does,” says Janne Juhola, partner at Innovestor.
The funding will go toward production that meets Good Manufacturing Practice (GMP) standards, which customers need before taking tissues made with the material into clinical trials. The round includes angels from the Finnish, Estonian, and Lithuanian business angel networks, alongside Innovestor’s Angel Cofund.
Published: November 16, 2026
